Introduction: Preparation and submission of regulatory dossiers is a core skill for B. Pharm students involved in pharmaceutical product approval. This topic covers dossier types (CTD, eCTD, DMF), module structure, CMC documentation, clinical and nonclinical data, stability studies, pharmacovigilance plans, and regulatory submission procedures. Understanding documentation standards, electronic submission formats, good documentation practice, and interactions with drug regulatory authorities helps ensure timely approval for quality, safety, and efficacy. Practical knowledge of dossier compilation, validation, response to queries, and lifecycle management prepares students for regulatory affairs roles. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What does CTD stand for in regulatory submissions?
- Common Technical Document
- Clinical Trial Dossier
- Company Technical Dossier
- Comprehensive Trial Data
Correct Answer: Common Technical Document
Q2. What is the primary difference between CTD and eCTD?
- CTD is paper-based while eCTD is electronic with an XML backbone
- CTD is for generics and eCTD is for innovators
- CTD contains only clinical data while eCTD contains only quality data
- CTD is a regional format while eCTD is only used by FDA
Correct Answer: CTD is paper-based while eCTD is electronic with an XML backbone
Q3. Which CTD module primarily contains Quality (CMC) information?
- Module 1
- Module 2
- Module 3
- Module 5
Correct Answer: Module 3
Q4. Clinical study reports and human data are located in which CTD module?
- Module 1
- Module 3
- Module 4
- Module 5
Correct Answer: Module 5
Q5. What is the purpose of a Drug Master File (DMF)?
- To provide manufacturing and confidential CMC information to regulators without revealing it to the applicant
- To register clinical trial sites
- To report post-marketing adverse events
- To request pricing approval from payers
Correct Answer: To provide manufacturing and confidential CMC information to regulators without revealing it to the applicant
Q6. In eCTD submissions, what is the primary organizational unit used to submit content to the regulator?
- Sequence
- Module bundle
- Packet
- Chapter
Correct Answer: Sequence
Q7. Which PDF format is commonly required for documents in eCTD submissions?
- PDF/A-1b
- PDF 2.0
- Standard printable PDF (no conformance)
- PDF/X-1a
Correct Answer: PDF/A-1b
Q8. Which international body harmonized the CTD format?
- World Health Organization (WHO)
- International Conference on Harmonisation (ICH)
- World Trade Organization (WTO)
- International Organization for Standardization (ISO)
Correct Answer: International Conference on Harmonisation (ICH)
Q9. Which document is typically required from a manufacturer to prove compliance with manufacturing standards?
- GMP certificate
- Marketing authorization letter
- Clinical trial protocol
- Price approval certificate
Correct Answer: GMP certificate
Q10. Which guideline is commonly referenced for conducting stability studies included in dossiers?
- ICH Q1A
- ICH Q5C
- ICH E2A
- ICH M4
Correct Answer: ICH Q1A
Q11. Which dossier document outlines plans for post-marketing safety monitoring and risk minimization?
- Pharmacovigilance Plan / Risk Management Plan
- Module 3 summary
- Certificate of analysis
- Manufacturing batch record
Correct Answer: Pharmacovigilance Plan / Risk Management Plan
Q12. What does ANDA stand for in regulatory submissions for generics?
- Abbreviated New Drug Application
- Advanced New Drug Application
- Authorized New Drug Application
- Approved New Drug Application
Correct Answer: Abbreviated New Drug Application
Q13. What is the common term for the regulator’s initial communication confirming a dossier has been accepted for review?
- Filing letter (acceptance letter)
- Inspection notice
- Approval certificate
- Request for additional fees
Correct Answer: Filing letter (acceptance letter)
Q14. Which of the following is NOT part of typical CMC documentation?
- Clinical trial protocols
- Specifications and analytical methods
- Manufacturing process description
- Stability data
Correct Answer: Clinical trial protocols
Q15. The eCTD backbone that organizes metadata and lifecycle operations is based on which technology?
- XML
- JSON
- PDF bookmarks only
- CSV manifests
Correct Answer: XML
Q16. The main regulatory aim of a dossier submission is to demonstrate which three attributes?
- Quality, safety and efficacy
- Marketing strategy, pricing, and distribution
- Patent strength, branding, and packaging
- Clinical site selection, investigator CVs, and budgets
Correct Answer: Quality, safety and efficacy
Q17. Who issues a Certificate of Pharmaceutical Product (CPP) used for regulatory submissions in importing countries?
- The national regulatory authority of the exporting (country of origin) manufacturer
- The World Health Organization
- The importing country’s pharmacy board
- The marketing authorization holder’s legal department
Correct Answer: The national regulatory authority of the exporting (country of origin) manufacturer
Q18. Which document is essential to include in a bioequivalence study report within a dossier?
- Validated bioanalytical method and its validation report
- Only the study protocol without analytical details
- Marketing plan for the generic product
- Price comparison with innovator drug
Correct Answer: Validated bioanalytical method and its validation report
Q19. In eCTD lifecycle management, which operation is used to replace an existing document with an updated version?
- Replace
- Append
- Withdraw
- Duplicate
Correct Answer: Replace
Q20. Which EU guidance deals specifically with batch certification and the role of the Qualified Person?
- EU GMP Annex 16
- EU GMP Annex 1
- ICH Q9
- EMA CTD Guidance
Correct Answer: EU GMP Annex 16
Q21. What process is used to remove or obscure sensitive commercial information before sharing documents with third parties?
- Redaction
- Compression
- Encryption only
- Pagination
Correct Answer: Redaction
Q22. Which CTD module is region-specific and contains administrative and prescribing information?
- Module 1
- Module 2
- Module 3
- Module 5
Correct Answer: Module 1
Q23. Which of the following is a common reason for regulatory rejection or refusal to file a dossier?
- Incomplete documentation or missing critical data
- High product price
- Small market size
- Lengthy clinical trial timelines
Correct Answer: Incomplete documentation or missing critical data
Q24. Who is primarily responsible for responding to deficiency letters or queries from the regulatory authority after submission?
- The applicant or marketing authorization holder
- The clinical trial subjects
- The site monitor
- The contract laboratory only
Correct Answer: The applicant or marketing authorization holder
Q25. Which CTD module contains nonclinical (toxicology and pharmacology) study reports?
- Module 4
- Module 2
- Module 3
- Module 1
Correct Answer: Module 4
Q26. What record documents the detailed stepwise process for producing a specific pharmaceutical batch?
- Batch Manufacturing Record
- Certificate of Pharmaceutical Product
- Ethics committee approval letter
- Marketing authorization
Correct Answer: Batch Manufacturing Record
Q27. What are bridging studies used for in regulatory submissions?
- To justify extrapolation between formulations, strengths, or manufacturing changes
- To substitute for all stability data
- To replace the need for clinical safety data
- To negotiate pricing with regulators
Correct Answer: To justify extrapolation between formulations, strengths, or manufacturing changes
Q28. In CTD, where are clinical summaries and overall clinical overviews placed?
- Module 2
- Module 3
- Module 4
- Module 5
Correct Answer: Module 2
Q29. Which practice ensures traceability and integrity of documents in an eCTD submission?
- Maintaining audit trails and version control
- Only using paper backups
- Deleting previous sequences after approval
- Using unstructured file names
Correct Answer: Maintaining audit trails and version control
Q30. What does a rolling submission allow a sponsor to do?
- Submit parts of the dossier in modules or sequences before the full submission is complete
- Delay submission indefinitely without regulator notification
- Submit only marketing materials without data
- Bypass inspection requirements
Correct Answer: Submit parts of the dossier in modules or sequences before the full submission is complete
